Business Context and Reporting Period
Company: IMMUCELL CORP
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2000
Business Overview: The Company operates in two segments: Animal Health Products and Research & Development (R&D). It primarily serves the U.S. dairy and beef industries, with key products including FIRST DEFENSE(R) and the KAMAR(R) HEATMOUNT(TM) DETECTOR.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2000 |
Six Months Ended June 30, 2000 |
|---|---|---|
| Total Revenues | $1,458,885 | $2,905,905 |
| Net Profit | $64,433 | $291,447 |
| Net Profit Per Share (Diluted) | $0.02 | $0.10 |
| Cash and Cash Equivalents | $1,785,153 (Ending Balance) | $1,785,153 (Ending Balance) |
| Net Cash from Operating Activities | N/A | $(294,483) (Used) |
| Total Debt (Current + Long Term) | $444,204 | $444,204 |
| Working Capital | $2,830,615 | $2,830,615 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 40% for the three months ended June 30, 2000, compared to the prior year period ($1.46M vs. $1.04M). Six-month revenues increased 19% ($2.91M vs. $2.45M).
- Product Sales: Product sales rose 44% in the quarter and 21% in the six-month period. This was driven by the shipment of backlogged FIRST DEFENSE(R) orders and increased sales of the KAMAR HEATMOUNT DETECTOR.
- Profitability: Net profit decreased slightly for the quarter ($64,433 vs. $78,983) and the six-month period ($291,447 vs. $332,882) despite revenue growth, primarily due to increased R&D expenses.
- Gross Margins: Gross margin as a percentage of product sales declined to 49% for the quarter (from 53%) and 51% for the six months (from 55%). Management attributes this to the introduction of WIPE OUT(TM) DAIRY WIPES, which carries a lower margin than FIRST DEFENSE.
- R&D Expenses: R&D expenses surged 73% in the quarter ($321,000 vs. $185,000) and 15% in the six-month period ($482,000 vs. $418,000) due to new product development initiatives.
- Cash Flow: Operating cash flow turned negative for the six-month period ($(294,483)), compared to positive cash flow of $244,373 in the prior year, largely due to increases in accounts receivable and inventory.
Outlook, Risks, and Management Commentary
- Outlook: Management believes current capital resources are sufficient to meet working capital requirements for the next 12 months. The Company anticipates continued profitable operations as funding requirements for animal health programs are lower than previous human health programs.
- R&D Focus: New investments are directed toward nisin-based treatments for mastitis and pathogen detection in water. Management notes that R&D expenses net of grant income were higher than the anticipated 12-14% of product sales due to the timing of Q2 expenditures.
- Regulatory Risks: Sales of TIP-TEST(TM): JOHNE'S have been limited by state regulatory barriers the Company is working to overcome.
- Grant Income: Grant income decreased significantly (from $54,269 to $21,157 in the quarter) as a percentage of total revenue, dropping from 5% to 1%.
- Forward-Looking Statements: The filing includes standard warnings regarding risks related to product development delays, regulatory approvals, and market competition.
Key Facts for Investor Verification
- Cash Burn vs. Profit: Verify the sustainability of operations given the negative operating cash flow of $(294,483) for the six months despite reporting a net profit of $291,447.
- Customer Concentration: Confirm the stability of the primary customer base, as 75-80% of product sales are concentrated in the U.S. dairy and beef industries.
- Margin Compression: Monitor the impact of the new WIPE OUT product line on overall gross margins, which have already declined year-over-year.
- Debt Obligations: Review the mortgage loan terms ($444,204 outstanding at 8.62%) and the balloon payment structure due in 2003.
- Regulatory Hurdles: Assess the timeline for overcoming state regulatory barriers affecting the TIP-TEST: JOHNE'S product line.